Sanara MedTech (SMTI) Cash & Equivalents (2010 - 2026)

Sanara MedTech (SMTI) has 17 years of Cash & Equivalents data on file, last reported at $13.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 34.29% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 34.29% YoY) and the FY2025 annual result came in at $16.6 million, up 4.41% from the prior year.
• Cash & Equivalents declined to $13.6 million in Q1 2026, from $16.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $20.7 million in Q1 2025 to a low of $2.8 million in Q1 2024.
• A 5-year average of $11.6 million and a median of $12.7 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 61.18% — and 2025, when it soared 631.47%.
• Tracing SMTI's Cash & Equivalents over 5 years: stood at $9.0 million in 2022, then tumbled by 42.55% to $5.1 million in 2023, then surged by 208.48% to $15.9 million in 2024, then grew by 4.41% to $16.6 million in 2025, then dropped by 18.0% to $13.6 million in 2026.
• The last three Cash & Equivalents figures came in at $13.6 million (Q1 2026), $16.6 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.